Retatrutide

‌Retatrutide (LY3437943) | GIP/GLP-1/GCGR Triple Agonist Peptide‌
🔹 ‌Product Overview‌
Retatrutide is a novel ‌triple agonist peptide‌ targeting GIP, GLP-1, and GCGR receptors, designed to regulate glucose metabolism and promote weight loss. It combines the therapeutic benefits of incretin hormones and glucagon activity, making it a breakthrough in metabolic disorder treatment. Primary applications include ‌obesity management‌ and ‌type 2 diabetes therapy‌ with enhanced efficacy compared to single-target agents‌15.

📌 ‌Key Advantages‌
✅ ‌Triple-Action Mechanism‌: Simultaneously activates GIP, GLP-1, and GCGR receptors for synergistic metabolic effects.
✅ ‌High Efficacy‌: Clinical trials show ‌≥15% weight reduction‌ in obese patients and ‌HbA1c reduction by 1.5-2.0%‌ in diabetics‌15.
✅ ‌Extended Half-Life‌: Engineered peptide structure ensures prolonged activity with once-weekly dosing.

🌐 ‌Application Areas‌

• ‌Obesity Treatment‌: Reduces appetite and enhances energy expenditure.

• ‌Type 2 Diabetes‌: Improves glycemic control and insulin sensitivity.

• ‌Cardiometabolic Health‌: Potential benefits in NAFLD (non-alcoholic fatty liver disease) and cardiovascular risk reduction‌.

🔍 ‌Quality & Compliance‌

• ‌HPLC purity ≥98%‌.

• Compliant with ‌USP/EP standards‌ for peptide synthesis and stability testing.

📈 ‌Market Trends‌
The global ‌anti-obesity drug market‌ is projected to reach ‌$54.8 billion by 2030‌ (CAGR 14.2%), driven by rising obesity rates and demand for multi-target therapies. Retatrutide’s triple-action profile positions it as a leader in next-generation metabolic treatments‌5.